iCAD Secure Six-System Mammography CAD Win in Spain

iCAD, Inc. (Nasdaq: ICAD), an industry leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announced the completion of a six-system sale to the Osakidetza Regional Health Care Service in the Basque region of Spain. To date, the systems have been installed with GE’s Essential platform and placed in the Hospital de Galdakao (Bilbao), the Hospital de Basurto (Bilabao), the Hospital de Deonostia (San Sebastian) and the Hospital Santiago Apostol (Vitoria).

SecondLook Digital is optimized for leading digital mammography systems including GE Healthcare and other leading manufacturers. In addition, iCAD’s SecondLook Digital provides powerful, flexible Digital Imaging and Communications in Medicine (DICOM) connectivity enabling universal compatibility with leading Picture Archiving Communication System (PACS) and Review Workstations. 

“We are honored to provide Osakidetza Regional Health Care Service with SecondLook CAD to highlight suspicious areas on their digital mammograms where further attention by a radiologist is warranted,” said Ken Ferry, President and CEO of iCAD. “We look forward to continued adoption of our CAD solutions in Europe and to a continued strong partnership with GE Healthcare that benefits patients worldwide.”

About SecondLook Digital

SecondLook Digital is designed to assist the radiologist in distinguishing cancers from other anomalies in the breast. SecondLook Digital is extremely proficient at detecting subtle cancers, or those that are most likely to be missed. SecondLook also provides workflow efficiencies that can improve the flow of patients within a mammography center.

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR)), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). Since receiving FDA approval for the Company’s first breast cancer detection product in 2002, over 3,200 iCAD systems have been placed in healthcare practices worldwide. iCAD’s solutions aid in the early detection of the most prevalent cancers including breast, prostate and in the future, colon and lung cancer. For more information, call (877) iCADnow or visit www.icadmed.com.

For iCAD, contact Darlene Deptula-Hicks at 603-882-5200 x7944, or via email at ddeptula@icadmed.com

For Investor Relations, contact Anne Marie Fields of Lippert/Heilshorn & Associates at 212-838-3777 x6604 or via email at afields@lhai.com

For media inquiries, contact Liza Heapes of MS&L PR
at 617-369-8787 or via e-mail at liza.heapes@mslworldwide.com

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.